Moreover, selective α4β2 and α7 nAChR subtype agonists AZD3480 and EVP-6124, respectively, demonstrated cognitive performance and attention improvement in patients with attention deficit hyperactivity disorder (ADHD) [12] and schizophrenia (SCH) [13]. Here, CHRNA7 is linked to attention deficit-hyperactivity disorder.